摘要：

Losartan potassium is a potent antihypertensive drug which is a highly specific Angiotensin II Type/AT1 receptor antagonist. It is readily absorbed from the gastro intestinal tract, having oral bioavailability 33% and plasma elimination half life from 1.5 to 2.5 hours. The present study is an attempt to increase therapeutic efficacy, reduce frequency of administration and improve patient compliance of Losartan potassium by developing sustained release tablets. Losartan potassium was formulated as oral sustained release tablets by using HPMC k4M and HPMC k15M. Preformulation studies were carried out to evaluate the parameters like powder flow properties, loss on drying, Drug-excipient compatibility and stress stability. All four formulations showed acceptable IP specifications for weight variation, thickness, hardness and friability. The dissolution studies showed release of drug over a period of 10 hours in zero-order kinetic.

展开